Chemours announced its financial results for the fourth quarter and full year 2024. During Q4 2024, the company reported net sales of $1.4 billion, in line with the corresponding prior-year quarter, with TSS achieving record fourth quarter net sales, driven by year-over-year growth of 23% in Opteon refrigerants. Net loss attributable to Chemours of $8 million, compared with a net loss attributable to Chemours of $18 million in the corresponding prior-year quarter.

During full year 2024, the company posted net sales of $5.8 billion compared to $6.1 billion in the prior year. Net Income attributable to Chemours of $86 million compared with a net loss attributable to Chemours of $238 million in the prior year.

“In the fourth quarter, we delivered a strong earnings performance, exceeding our Adjusted EBITDA expectations across all our businesses. For TSS5, we set another quarterly Net Sales record, with 23% year-over-year growth in Opteon Refrigerants. In parallel, we continued to drive strong commercial performance while executing our transformation efforts in TT, and we took advantage of cost opportunities in APM,” said Denise Dignam, Chemours President and CEO.

“We are well underway executing our Pathway to Thrive strategy, as evidenced by our recent strong performance, leadership announcements, partner agreement for on-site chlorine production at our DeLisle TiO2 facility, and the recent completion of the neat Opteon™ capacity expansion at our Corpus Christi, Texas site. While 2024 was a year of transition for Chemours, with a refreshed management team and strategy, we have the right pieces in place to move forward. Our Pathway to Thrive strategy is the key to driving long-term shareholder value, and our progress through the end of the year reinforces that confidence for 2025 and beyond.”

The company expects to deliver 2025 Adjusted EBITDA of $825 million to $975 million. Operating cash flow is expected to improve as the year progresses and more than fund anticipated capital expenditures ranging from $250 million to $300 million, while also ensuring dividend funding, subject to Board approval quarterly.